Sarepta Therapeutics, Inc.

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
129.1 ^USD	-1.31%		-2.67%	+33.90%

May. 17	Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	MT
May. 14	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	MT

Sarepta Therapeutics, Inc. Elects Ryan Brown as General Counsel

March 01, 2021 at 04:30 pm EST

Sarepta Therapeutics, Inc. elected Ryan Brown, formerly Chief Compliance Officer and then Interim Head of Legal and Compliance function to be permanent General Counsel.

Latest news about Sarepta Therapeutics, Inc.

Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	May. 17	MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	May. 14	MT
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	May. 02	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	May. 02	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	May. 02	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	May. 01	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	May. 01	MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	May. 01	MT
Transcript : Sarepta Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	May. 01
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21	RE
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM	Mar. 12
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	Mar. 12	MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM	Mar. 11
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	Mar. 07	MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	Mar. 01	MT
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	Feb. 29	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	Feb. 29	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	Feb. 29	MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28	MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	Feb. 28	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI

Chart Sarepta Therapeutics, Inc.

Duration

Period

More charts

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Sarepta Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

129.1 USD

Average target price

168.2 USD

Spread / Average Target

+30.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.33%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B
VAXCYTE, INC.	+17.28%	8.01B

Bio Therapeutic Drugs